Ankit Mahadevia, CEO and President at Spero Therapeutics, Inc. (SPRO), sold 16,877 shares at $14.43 ($243K) on 2020-11-04, disclosed to the SEC on 2020-11-05.
Open-market sale of $243k SPRO by CEO and President. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $14.27 | 2,137 | $30K | 12.5% |
| 2 | $14.43 | 7,370 | $106K | 43.7% |
| 3 | $14.43 | 7,370 | $106K | 43.7% |
| Total | $14.41 avg | 16,877 | $243K | 100% |
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2024-02-05 | $175K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |